Hematology Oncology of Indiana’s M. Sarfraz Nawaz, MD, investigated improvement in approaches to febrile neutropenia in cancer patients and presented research at the International Lymphoma Symposium. Read the press release > https://hubs.li/Q02G9Tcx0 #cancercare
American Oncology Network’s Post
More Relevant Posts
-
In this episode of #OncLiveOnAir, Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology. #mmsm #oncology https://lnkd.in/eywTGN7N
To view or add a comment, sign in
-
European School of Oncology - Certificate of Advanced Studies in Lymphomas launched in collaboration with Ulm University The European School of Oncology, in collaboration with Ulm University, has launched the seventh cohort of the Certificate of Advanced Studies in Lymphomas. This program offers in-depth scientific and practical insights to enhance expertise in managing lymphoma patients. https://lnkd.in/exYx_4fT #OncoDaily #Oncology #Cancer #Health #Medicine #Lymphoma #Collaboration
To view or add a comment, sign in
-
World Lymphoma Awareness Day is coming, we can do more together. Medicilon has many effective models for evaluating new drugs for lymphoma and leukemia. Click to view more tumor models: https://lnkd.in/gQCeSzQd #lymphoma #cancer #medicilon
To view or add a comment, sign in
-
CAR-T Cell Therapy brings a new ray of hope in the fight against cancer. It has shown unprecedented response rates in patients with B-cell leukemia and lymphoma who were no longer responding to chemotherapy. In older patients with comorbidities and patients whose Bone Marrow Transplant relapsed, CAR-T Cell Therapy can be beneficial. Dr. Esha Kaul, Director - Haematology, Hemato – Oncology & BMT, Max Institute of Cancer Care, Vaishali, Delhi, India, sheds light on the transformative benefits of this therapy in this video. Watch to know more. #CARTcellTherapy #CancerTreatment #Oncology #MaxHealthcare
To view or add a comment, sign in
-
🌟 Interview with Dr. Michael Wang – Exciting Developments in Lymphoma Treatment! 🌟 In a recent Hematology Frontier interview, Dr. Michael Wang shared insights from the EHA Late Breaker Plenary Session, where the pivotal ECHO clinical trial was discussed. the study is leading to breakthroughs in lymphoma care. The promising combination of BR + Acalabrutinib shows potential to improve outcomes, especially for older patients. This could pave the way for better therapies globally! 🌍💉 #LymphomaResearch #ClinicalTrials #CancerTreatment #EHA #BRTherapy #ECHOStudy #MedicalInnovation #Oncology #CancerCare #QualityOfLife #Hematology #OncologyFrontiers
To view or add a comment, sign in
-
See this month’s highlights from the ESMO - European Society for Medical Oncology portfolio - Oncology Advance Elsevier Oncology Annals of Research in Oncology #Cancer #CancerTreatment #ESMO #Leukemia #LungCancer #Lymphoma #Myeloma #OncoDaily #Oncology #OncologyAdvance
To view or add a comment, sign in
-
Dr. Alex Ricart explores the exciting advancements of Antibody-Drug Conjugates (ADCs) in treating cancers like leukemia, lymphoma, and solid tumors. Learn how approved ADCs are enhancing traditional chemotherapy, innovative study designs, and future breakthroughs like new antibody fragments and hydrophilic linkers. Watch now: https://lnkd.in/eVEpZnMH #CancerResearch #ADCTherapies #OncologyInnovation
To view or add a comment, sign in
-
On #WorldBloodCancerDay, we’re taking a moment to recognize the need for transformational treatments for people across the globe who are diagnosed with lymphoma, leukemia or myeloma each day. At ADC Therapeutics, we’re working with urgency to develop #antibodydrugconjugates in areas of high unmet need to bring hope to patients with #cancer, including hematologic cancers. #WBCD
To view or add a comment, sign in
-
Here’s a good read that offers some insight into the future of lymphoma and blood cancer treatments. It is undeniable that progress to date is based on scientific research and strong support and hard work from all stakeholders. I’m currently in a clinical trial using a bi-specific agent called Mosunetuzamab (Mosun for short). So far, it seems pretty clear to me that this targeted therapy, not without risks, is more tolerable than conventional regimens. Thanks to Dr. LaCasce and LRF for shepherding innovations in therapy and for setting the stage for a bright and optimistic future in fulfilling the mission to one day eradicate lymphoma.
As we kick off 2024, the year ahead looks to be an especially bright one for breakthroughs in lymphoma research. LRF's Scientific Advisory Board chair Dr. Ann LaCasce (Dana-Farber Cancer Institute) shares some of the most promising innovations and advancements with Targeted Oncology: https://lnkd.in/epBJpHdp
LaCasce Shares Hopes for 2024, Highlighting Advancements Across Lymphomas
To view or add a comment, sign in
-
The Vessel of Hope for Peripheral T-Cell Lymphoma Braves the Storm and Forges Ahead Fearlessly - Owen A. O'Connor, M.D., Ph.D. MediaMedic https://lnkd.in/eMBJvNwz #Cancer #CancerTreatment #Chemotherapy #ClinicalOncology #ClinicalTrial #TumorResearch #Oncology #MediaMedic #OncoDaily
To view or add a comment, sign in
19,334 followers